Volume 138, Issue 1, Pages (January 2010)

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

Advertisements

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Volume 149, Issue 6, Pages (November 2015)

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen? Patrick Marcellin, E. Jenny Heathcote,

Volume 137, Issue 3, Pages e1 (September 2009)

Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis

Covering the Cover Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis Lorenzo Loffredo, Daniele Pastori,

Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis

New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges

Effectiveness of Hepatitis B Treatment in Clinical Practice

Volume 153, Issue 4, Pages (October 2017)

Outcomes Among Living Liver Donors

Peginterferon alfa-2b plus ribavirin for chronic hepatitis

Improved Virologic Response in Chronic Hepatitis C Genotype 4 Treated With Nitazoxanide, Peginterferon, and Ribavirin Jean–François Rossignol, Asem Elfert,

Ira J. Fox, Stephen C. Strom Gastroenterology

Volume 141, Issue 3, Pages e1 (September 2011)

Volume 41, Issue 3, Pages (September 2004)

Volume 140, Issue 2, Pages e1 (February 2011)

A Historical Perspective on Clinical Advances in Pancreatic Diseases

Volume 150, Issue 4, Pages (April 2016)

Volume 154, Issue 4, Pages (March 2018)

Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis Lorenzo Loffredo, Daniele Pastori,

Volume 133, Issue 5, Pages (November 2007)

Volume 155, Issue 5, Pages e2 (November 2018)

No Differences in Achieving Hepatitis C Virus Care Milestones Between Patients Identified by Birth Cohort or Risk-Based Screening Brianna L. Norton,

Volume 152, Issue 1, Pages e4 (January 2017)

Volume 130, Issue 4, Pages (April 2006)

Hepatitis C and Hepatocellular Carcinoma: Grist for the Mill

The Combination of Simeprevir and Sofosbuvir Is More Effective Than That of Peginterferon, Ribavirin, and Sofosbuvir for Patients With Hepatitis C–Related.

Ashutosh Gupta, Bashar M. Attar, Vikram Kotwal

Volume 130, Issue 3, Pages (March 2006)

Volume 142, Issue 6, Pages (May 2012)

Volume 144, Issue 7, Pages e2 (June 2013)

Rafael Esteban, Maria Buti Gastroenterology

Volume 136, Issue 5, Pages (May 2009)

Low-Dose Peginterferon Alfa-2a Is Safe and Produces a Sustained Virologic Response in Patients With Chronic Hepatitis C and End-Stage Renal Disease Markus.

Volume 145, Issue 4, Pages e3 (October 2013)

Ashwin N. Ananthakrishnan, David Lieberman Gastroenterology

Volume 148, Issue 3, Pages (March 2015)

Genetic Factors and Hepatitis C Virus Infection

Electronic Clinical Challenges and Images in GI

Alan Bonder, MD, Nezam H. Afdhal, MD

Volume 139, Issue 6, Pages (December 2010)

Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals.

Statin Therapy Improves Sustained Virologic Response Among Diabetic Patients With Chronic Hepatitis C Gowtham A. Rao, Prashant K. Pandya Gastroenterology

Covering the Cover Gastroenterology

The Dawning of a New Editorial Board for Gastroenterology

Volume 136, Issue 5, Pages e2 (May 2009)

Alessio Aghemo, Maria Francesca Donato Gastroenterology

Hepatitis C treatment in patients with kidney disease

This Month in Gastroenterology

Covering the Cover Gastroenterology

Volume 147, Issue 2, Pages e1 (August 2014)

Volume 132, Issue 1, Pages (January 2007)

Changing of the Guards: 2011–2016 Gastroenterology Team

Volume 156, Issue 4, Pages (March 2019)

Meta-analysis Shows Extended Therapy Improves Response of Patients With Chronic Hepatitis C Virus Genotype 1 Infection Harald Farnik, Christian M. Lange,

Volume 156, Issue 3, Pages (February 2019)

Michelle Maria Pietzak Gastroenterology

Volume 155, Issue 6, Pages (December 2018)

Volume 139, Issue 6, Pages e1 (December 2010)

Volume 139, Issue 5, Pages (November 2010)

Volume 147, Issue 6, Pages (December 2014)

Volume 135, Issue 2, Pages (August 2008)

Detection of HCV RNA in Sustained Virologic Response to Direct-Acting Antiviral Agents: Occult or Science Fiction? Masaru Enomoto, Yoshiki Murakami,

Controversies in Liver Transplantation for Hepatitis C

The Results of Phase III Clinical Trials With Telaprevir and Boceprevir Presented at the Liver Meeting 2010: A New Standard of Care for Hepatitis C Virus.

Presentation transcript:

Volume 138, Issue 1, Pages 108-115 (January 2010) Randomized Study of Peginterferon-α2a Plus Ribavirin vs Peginterferon-α2b Plus Ribavirin in Chronic Hepatitis C Maria Grazia Rumi, Alessio Aghemo, Gian Maria Prati, Roberta D'Ambrosio, Maria Francesca Donato, Roberta Soffredini, Ersilio Del Ninno, Antonio Russo, Massimo Colombo Gastroenterology Volume 138, Issue 1, Pages 108-115 (January 2010) DOI: 10.1053/j.gastro.2009.08.071 Copyright © 2010 AGA Institute Terms and Conditions

Figure 1 Flow chart of the MIST study. aNineteen patients met the week 12 stopping rule, 7 patients met the week 24 stopping rule, and 2 patients had a virologic breakthrough. Twenty of 28 patients were HCV-1, and 8 were HCV-4. bThirty-two patients met the week 12 stopping rule; 15 patients met the week 4 stopping rule; and 3 patients had a virologic breakthrough. Thirty-five of 50 patients were HCV-1, and 15 were HCV-4. Gastroenterology 2010 138, 108-115DOI: (10.1053/j.gastro.2009.08.071) Copyright © 2010 AGA Institute Terms and Conditions

Figure 2 Rates of virologic response for the patients with chronic hepatitis C receiving RBV combined with PegIFN-α2a or PegIFN-α2b. RVR, rapid; cEVR, complete early; EOT, end of treatment; and SVR, sustained virologic. Gastroenterology 2010 138, 108-115DOI: (10.1053/j.gastro.2009.08.071) Copyright © 2010 AGA Institute Terms and Conditions